A Rare Case of Demodicosis Following Treatment With Oral Fluconazole

por Bezecny, Joshua A, Bolton, Emily, Taylor, Matthew H, Berry, Elizabeth G
Publicado 2023

TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms

por Duvoisin, Robert M., Ren, Gaoying, Haley, Tammie L., Taylor, Matthew H., Morgans, Catherine W.
Publicado 2019

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

por Gianoukakis, Andrew G, Flores, Natalia M, Pelletier, Corey L, Forsythe, Anna, Wolfe, Gregory R, Taylor, Matthew H
Publicado 2016

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies

por Taylor, Matthew H., Alva, Ajjai S., Larson, Timothy, Szpakowski, Sebastian, Purkaystha, Das, Amin, Alpesh, Karpiak, Linda, Piha-Paul, Sarina A.
Publicado 2020

Prediction of Thorough QT study results using action potential simulations based on ion channel screens

por Mirams, Gary R., Davies, Mark R., Brough, Stephen J., Bridgland-Taylor, Matthew H., Cui, Yi, Gavaghan, David J., Abi-Gerges, Najah
Publicado 2014

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab

por Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Publicado 2021

The ploidy-conveyor of mature hepatocytes as a source of genetic variation

por Duncan, Andrew W., Taylor, Matthew H., Hickey, Raymond D., Hanlon Newell, Amy E., Lenzi, Michelle L., Olson, Susan B., Finegold, Milton J., Grompe, Markus
Publicado 2010

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

por Taylor, Matthew H., Lee, Chung-Han, Makker, Vicky, Rasco, Drew, Dutcus, Corina E., Wu, Jane, Stepan, Daniel E., Shumaker, Robert C., Motzer, Robert J.
Publicado 2020

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

por Kiyota, Naomi, Robinson, Bruce, Shah, Manisha, Hoff, Ana O., Taylor, Matthew H., Li, Di, Dutcus, Corina E., Lee, Eun Kyung, Kim, Sung-Bae, Tahara, Makoto
Publicado 2017

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

por Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J., Dutcus, Corina E., Song, James, Taylor, Matthew H., Kim, Sung-Bae, Krzyzanowska, Monika K., Capdevila, Jaume, Sherman, Steven I., Tahara, Makoto
Publicado 2016

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

por Piha-Paul, Sarina A., Taylor, Matthew H., Spitz, Daniel, Schwartzberg, Lee, Beck, J. Thaddeus, Bauer, Todd M., Meric-Bernstam, Funda, Purkayastha, Das, Karpiak, Linda, Szpakowski, Sebastian, Braiteh, Fadi
Publicado 2019

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

por Kelly, Karen, Infante, Jeffrey R., Taylor, Matthew H., Patel, Manish R., Wong, Deborah J., Iannotti, Nicholas, Mehnert, Janice M., Loos, Anja H., Koch, Helga, Speit, Isabell, Gulley, James L.
Publicado 2018

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib

por Taylor, Matthew H., Takahashi, Shunji, Capdevila, Jaume, Tahara, Makoto, Leboulleux, Sophie, Kiyota, Naomi, Dutcus, Corina E., Xie, Ran, Robinson, Bruce, Sherman, Steven, Habra, Mouhammed Amir, Elisei, Rossella, Wirth, Lori J.
Publicado 2021

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

por Makker, Vicky, Aghajanian, Carol, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., Messing, Mark, Dutta, Lea, Dutcus, Corina E., Huang, Jie, Schmidt, Emmett V., Orlowski, Robert, Taylor, Matthew H.
Publicado 2023

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

por Hrinczenko, Borys, Iannotti, Nicholas, Goel, Sanjay, Spigel, David, Safran, Howard, Taylor, Matthew H, Bennouna, Jaafar, Wong, Deborah J, Kelly, Karen, Verschraegen, Claire, Bajars, Marcis, Manitz, Juliane, Ruisi, Mary, Gulley, James L
Publicado 2022

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

por Motzer, Robert J., Taylor, Matthew H., Evans, Thomas R. Jeffry, Okusaka, Takuji, Glen, Hilary, Lubiniecki, Gregory M., Dutcus, Corina, Smith, Alan D., Okpara, Chinyere E., Hussein, Ziad, Hayato, Seiichi, Tamai, Toshiyuki, Makker, Vicky
Publicado 2022

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

por Powderly, John D, Klempner, Samuel J, Naing, Aung, Bendell, Johanna, Garrido-Laguna, Ignacio, Catenacci, Daniel V T, Taylor, Matthew H, Lee, James J, Zheng, Fred, Zhou, Feng, Gong, Xiaohua, Gowda, Hema, Beatty, Gregory L
Publicado 2022

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

por Keilholz, Ulrich, Mehnert, Janice M., Bauer, Sebastian, Bourgeois, Hugues, Patel, Manish R., Gravenor, Donald, Nemunaitis, John J., Taylor, Matthew H., Wyrwicz, Lucjan, Lee, Keun-Wook, Kasturi, Vijay, Chin, Kevin, von Heydebreck, Anja, Gulley, James L.
Publicado 2019

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

por Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Publicado 2021

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

por Taylor, Matthew H., Betts, Courtney B., Maloney, Lauren, Nadler, Eric, Algazi, Alain, Guarino, Michael J., Nemunaitis, John, Jimeno, Antonio, Patel, Priti, Munugalavadla, Veerendra, Tao, Lin, Adkins, Douglas, Goldschmidt, Jerome H., Cohen, Ezra E.W., Coussens, Lisa M.
Publicado 2022